- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
473
ANLUOHUAXIANWAN COMBINED WITH ENTECAVIR THERAPY
ENHANCES FIBROSIS IMPROVEMENT RATE IN PATIENTS WITH
CHB: A MULTICENTER, RANDOMIZED, PROSPECTIVE STUDY
Liang Miao1,2, Wan-Na Yang1, Xiaoqin Dong1, Hong Zhao1 and
Guiqiang Wang3, (1)Infectious Diseases, Peking University
First Hospital, (2)Center of Diseases, The Third Hospital of
Qinhuangddao, (3)Department of Infectious Diseases, Peking
University First Hospital
Background: Limited reliable data are available regarding
changes in fibrosis in patients treated with anluohuaxianwan
(ALHXW) combined with entecavir (ETV). The aim of this study
was to evaluate changes in fibrosis between groups treated
with ALHXW combined with ETV and ETV alone. Methods:
219 consecutive chronic hepatitis B (CHB) paired liver
biopsies obtained before and after treatment from patients in
mainland China were analyzed, including 77 in the ETV group
and 142 in the ALHXW combined with ETV group. Histological
grading and staging were assessed using the Ishak scoring
system Results: In patients with Ishak score ≥3 at baseline,
the fibrosis improvement rate of combined therapy after 78
weeks (54.74%, 52/95) was significantly higher than that of
the monotherapy group (33 33%,16/48), P =0 016; In patients
with Ishak score <3 at baseline, the rate of patients with
increased fibrosis in the combination group (31.91%, 15/47 )
was less than that of the monotherapy group (48 28%,14/29)
Multivariate analyses addressed that combination therapy
(OR=2.655, P=0.038), high baseline fibrosis stage
(OR=1 797, P=0 019), low HBsAg (OR=1 951, P=0 029),
and young age (OR=0 954, P=0 014) were associated with
fibrosis regression after 78 weeks intervention. Conclusion:
Significantly higher fibrosis improvement rate was found in
ALHXW combined with ETV therapy for 78 weeks in patients
with baseline Isake score ≥ 3. Of these patients, high baseline
fibrosis stage (Ishak score ≥3), low HBsAg, and young age
potentially predicte regression.
|
|